In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms.
Adult
Aged
Animals
Animals, Genetically Modified
Antigens, Neoplasm
/ biosynthesis
Bombyx
Female
Head and Neck Neoplasms
/ diagnosis
Humans
Immune System
Immunity
Immunohistochemistry
Immunotherapy
/ methods
In Vitro Techniques
Kaplan-Meier Estimate
Leukocytes, Mononuclear
/ cytology
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Progression-Free Survival
Tumor Suppressor Protein p53
/ biosynthesis
Journal
Journal of materials science. Materials in medicine
ISSN: 1573-4838
Titre abrégé: J Mater Sci Mater Med
Pays: United States
ID NLM: 9013087
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
13
06
2020
accepted:
09
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
21
12
2021
Statut:
epublish
Résumé
The evaluation of antitumor immune responses is essential for immune monitoring to predict clinical outcomes as well as treatment efficacies in cancer patients. In this study, we produced two tumor antigen (TA) proteins, melanoma antigen family A4 and wild type p53, using TG silkworm systems and evaluated anti-TA-specific immune responses by enzyme-linked immunosorbent spot assays in patients with head and neck cancer. Eleven (61.1%) of 18 patients showed significant IFN-γ production in response to at least one TA; however, the presence of TA-specific immune responses did not significantly contribute to better prognosis (overall survival, p = 0.1768; progression-free survival, p = 0.4507). Further studies will need to be performed on a larger scale to better assess the clinical significance of these systems. The production of multiple TA proteins may provide new avenues for the development of immunotherapeutic strategies to stimulate a potent and specific immune response against tumor cells as well as precise assessment of antitumor immune responses in cancer patients.
Identifiants
pubmed: 33999320
doi: 10.1007/s10856-021-06526-6
pii: 10.1007/s10856-021-06526-6
pmc: PMC8128804
doi:
Substances chimiques
Antigens, Neoplasm
0
MAGEA4 protein, human
0
Neoplasm Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Références
J Biochem. 2009 Jan;145(1):37-42
pubmed: 18984628
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Genes Cancer. 2011 Apr;2(4):466-74
pubmed: 21779514
Biotechnol Lett. 2011 Apr;33(4):645-54
pubmed: 21184136
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Curr Opin Mol Ther. 2001 Feb;3(1):45-52
pubmed: 11249731
Blood. 2008 Oct 15;112(8):3362-72
pubmed: 18658027
Cancer Immunol Immunother. 2018 Jul;67(7):1031-1040
pubmed: 29541787
Eur J Immunol. 2017 Jul;47(7):1232-1242
pubmed: 28555838
Drug Discov Ther. 2016 Feb;10(1):34-9
pubmed: 26971553
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Vaccine. 2014 Oct 14;32(45):5901-7
pubmed: 25218300
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Exp Med. 2019 Jun 3;216(6):1244-1254
pubmed: 31068379
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
PLoS One. 2011;6(8):e23651
pubmed: 21858191
Eur J Cancer. 2016 Jul;61:77-84
pubmed: 27155446
Nat Biotechnol. 2003 Jan;21(1):52-6
pubmed: 12483223
Cancer Res. 2000 Sep 1;60(17):4850-4
pubmed: 10987297
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075
pubmed: 29385894
Biochem Biophys Res Commun. 2007 Apr 20;355(4):976-80
pubmed: 17335775
Mol Cell. 2010 Sep 24;39(6):963-74
pubmed: 20864041
Exp Ther Med. 2018 Mar;15(3):2512-2518
pubmed: 29563979
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
Cancer Immunol Immunother. 2014 Jan;63(1):45-57
pubmed: 24100804
Br J Cancer. 2014 May 13;110(10):2506-13
pubmed: 24762957
Theranostics. 2019 Oct 15;9(25):7807-7825
pubmed: 31695802
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Mol Oncol. 2015 Dec;9(10):2054-62
pubmed: 26607741
NPJ Vaccines. 2019 Feb 8;4:7
pubmed: 30774998
Clin Cancer Res. 2001 May;7(5):1127-35
pubmed: 11350875
Eur J Pharmacol. 2017 Nov 5;814:130-137
pubmed: 28823924
Ecancermedicalscience. 2014 Jul 02;8:441
pubmed: 25075215